Clinical development of AKP-022 (relugolix combination drug) through Phases I/II and III
A standalone clinical development program for AKP-022, a relugolix combination drug, for which a Phase I/II trial began in July 2023 and which advanced to Phase III in June 2025.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.